RPE65 and Leber congenital amaurosis: Despite the marginal improvement of vision and the variability of outcomes between trials, the promising results of the early clinical trials in the management of choroideremia highlight the prospects for genetic therapy in diseases beyond RPE65 mutation-mediated LCA.